Zacks Research Issues Optimistic Estimate for GSK Earnings

GSK plc (NYSE:GSK) – Equities research analysts at Zacks Research lifted their Q2 2025 earnings estimates for GSK in a research note issued on Wednesday, May 21st. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will earn $1.08 per share for the quarter, up from their previous forecast of $1.05. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $0.87 EPS, FY2025 earnings at $4.36 EPS, Q3 2026 earnings at $1.42 EPS, Q4 2026 earnings at $1.09 EPS and FY2027 earnings at $4.93 EPS.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. GSK’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.43 EPS.

Other analysts have also recently issued reports about the company. Morgan Stanley started coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. BNP Paribas initiated coverage on GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 target price for the company. Hsbc Global Res raised shares of GSK to a “strong sell” rating in a research report on Monday, April 28th. Finally, Wall Street Zen raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $40.58.

GSK Trading Down 0.6%

Shares of NYSE:GSK opened at $38.70 on Friday. GSK has a 12-month low of $31.72 and a 12-month high of $45.01. The business has a 50 day moving average of $37.27 and a 200-day moving average of $36.03. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The stock has a market cap of $79.84 billion, a PE ratio of 24.34, a P/E/G ratio of 1.12 and a beta of 0.51.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. HB Wealth Management LLC acquired a new position in shares of GSK in the 4th quarter valued at approximately $316,000. Ballentine Partners LLC increased its stake in GSK by 40.7% in the fourth quarter. Ballentine Partners LLC now owns 17,150 shares of the pharmaceutical company’s stock valued at $580,000 after acquiring an additional 4,959 shares during the last quarter. Kelleher Financial Advisors raised its position in GSK by 13.5% during the fourth quarter. Kelleher Financial Advisors now owns 11,387 shares of the pharmaceutical company’s stock valued at $385,000 after purchasing an additional 1,357 shares in the last quarter. Brighton Jones LLC bought a new stake in GSK during the fourth quarter worth $528,000. Finally, Geneos Wealth Management Inc. bought a new stake in GSK during the fourth quarter worth $145,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a $0.4216 dividend. The ex-dividend date is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.36%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is presently 86.60%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.